Rukobia Medical Information - Our HIV Medications

Prescribing Information

Patient Information

Medical Information Documents
Overview of HTE Patients

Overview (MI letter)

HTE Resources

BRIGHTE Study

Immunologic Recovery

Use with Ibalizumab

BRIGHTE Overview

BRIGHTE (MI letter)

BRIGHTE (Infographic)

Week 96 Results (IAS 2019)

Prior ARV Exposure and Optimized Background Therapy

OBT (MI letter)

OBT (Infographic)

Clinical Pharmacology

MOA (MI letter)

CNS Penetration

Binding Affinity/Dissociation

Viral Susceptibility and Cross-Resistance

Viral susceptibility (MI letter)

Viral susceptibility (Infographic)

Safety Data

Safety Summary

QTc Prolongation

Data in Pregnancy

Drug-Drug Interactions

DDI Overview

Once Daily Use

Once Daily Use

Storage and Stability

Splitting/Crushing

Storage Conditions
Recent Congress Data
On Demand Medical Videos
Dosing

Fostemsavir Clinical Pharmacology Overview
Golkoo Morcos, PharmD, Medical Science Liaison

MOA

Fostemsavir Mechanism of Action
Golkoo Morcos, PharmD, Medical Science Liaison

On Demand

Discussing the BRIGHTE Study at AIDS 2022
Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Research Center and Found of Midway Specialty Care Centers

Caring for Patients with Multidrug Resistant (MDR) HIV - A Focus on Patient Identification and ARV Management with Q&A
Alftan Dyson, PharmD | Bruce Gilliam, MD | Elizabeth Race, MD, MPH| Moti Ramgopal, MD, FACP, FIDSA

Pharmacokinetics

Fostemsavir Clinical Pharmacology Overview
Golkoo Morcos, PharmD, Medical Science Liaison

Virology/Resistance

Viral Susceptibility of Rukobia
Golkoo Morcos, PharmD, US Medical Director

Clinical Pharmacology

Clinical Pharmacology Overview

MOA Overview (Video)

Viral Susceptibility and Cross-Resistance

Viral susceptibility (Video)

Data with IBA or MVC (CROI 2021)
External Resources

For more information on Genotype interpretation, visit the following resources:

ANRS HIV French Resistance
www.hivfrenchresistance.org

IAS-USA, website
www.iasusa.org

Los Alamos database
www.hiv.lanl.gov

Stanford HIV Drug Resistance database
hivdb.stanford.edu

For more information on OBT construction for specific patient, visit the following resources:

HIV-ASSIST

Welcome to HIV-ASSIST | HIV-ASSIST (hivassist.com)

AIDS Education Training Center

National Coordinating Resource Center
aidsetc.org

Regional AETCs

http://aidsetc.org/aetc-program/regional-offices

Mayo Clinic: POINT-OF-CARE CME – Highly Treatment–Experienced and Complex HIV Cases (Education and Research at Mayo Clinic - Education and Research at Mayo Clinic)

POINT-OF-CARE CME - Highly Treatment–Experienced and Complex HIV Cases

Medscape
www.medscape.com

National Clinical Consultation Center
nccc.ucsf.edu/clinical-resources/hiv-aids-resources

For more information on General Information about OBT Construction, visit the following resources:

Clinical Care Options
www.clinicaloptions.com/hiv

DHHS Guidelines
https://clinicalinfo.hiv.gov/

Medscape
www.medscape.com

National HIV Curriculum
www.hiv.uw.edu

Practice Point
www.practicepointcme.com

UCSF HIV InSITE
http://hivinsite.ucsf.edu

Up to date
www.uptodate.com

Connect With Us

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes